Renal infarction Medical Services in China

Renal infarction is a rare but potentially serious condition characterized by ischemic necrosis of renal parenchyma due to abrupt occlusion of the renal artery or its branches—most commonly from embolic or thrombotic events. Unlike chronic renal ischemia, renal infarction presents acutely and demands prompt recognition to prevent irreversible loss of renal function, systemic complications (e.g., hypertension, acute kidney injury), or septic sequelae if infarcted tissue becomes infected. Pathogenesis centers on vascular obstruction: emboli—often originating from atrial fibrillation, valvular heart disease, or left ventricular thrombi—account for ~60–70% of cases; in situ thrombosis may occur in settings of vasculitis (e.g., polyarteritis nodosa), hypercoagulable states (e.g., antiphospholipid syndrome, malignancy), or trauma-related arterial injury. Less common causes include renal artery dissection, fibromuscular dysplasia, or paradoxical embolism via patent foramen ovale. Epidemiologically, renal infarction is underdiagnosed, with an estimated incidence of 0.03–0.1% among hospitalized adults undergoing abdominal imaging; it peaks in the sixth to seventh decades, with slight male predominance. Risk factors include cardiovascular comorbidities (atrial fibrillation, recent myocardial infarction, mechanical heart valves), inherited or acquired thrombophilias, active malignancy, endocarditis, and prior history of systemic embolism. Clinical presentation is highly variable: up to 30% of cases are asymptomatic and detected incidentally on CT or MRI; symptomatic patients typically present with sudden-onset flank or abdominal pain (often unilateral), low-grade fever, nausea, hematuria, and elevated lactate dehydrogenase (LDH) or D-dimer. Serum creatinine may remain normal initially—even with substantial infarct volume—making imaging (contrast-enhanced CT or MRI) essential for diagnosis. Delayed diagnosis increases risks of chronic kidney disease progression, hypertension secondary to renin-mediated activation, and reduced quality of life due to persistent pain, fatigue, anxiety about recurrent events, and limitations in physical activity or employment. Patients often experience significant psychological burden—including health-related anxiety and uncertainty—especially when underlying cardiac or thrombotic conditions require lifelong anticoagulation and multidisciplinary follow-up. Early intervention improves renal salvage potential, though functional recovery depends on infarct size, collateral circulation, and timeliness of reperfusion strategies. Long-term management emphasizes secondary prevention: anticoagulation (e.g., DOACs or warfarin), cardiovascular risk optimization, and surveillance for recurrence or contralateral involvement.

Renal infarction is a rare but potentially serious condition resulting from abrupt occlusion of the renal artery or its branches—most commonly due to embolism (e.g., from atrial fibrillation, valvular heart disease, or left ventricular thrombus), thrombosis (e.g., in vasculitis, antiphospholipid syndrome, or hypercoagulable states), or less frequently, trauma or iatrogenic injury. Clinical presentation is often nonspecific and may include acute flank or abdominal pain, fever, hematuria, elevated serum lactate dehydrogenase (LDH), and rising creatinine—though up to 30% of cases are asymptomatic and detected incidentally on imaging. Prompt diagnosis via contrast-enhanced CT angiography or MRI is critical, as delayed intervention risks irreversible cortical necrosis, hypertension secondary to renin-mediated activation, and progressive chronic kidney disease.

Conservative management is appropriate for hemodynamically stable patients with small, peripheral infarcts (<25% of renal volume), preserved renal function, and no evidence of ongoing embolic source or systemic complications. This approach emphasizes close monitoring of vital signs, serial renal function tests (serum creatinine, estimated GFR, electrolytes), urinalysis, and inflammatory markers (CRP, LDH). Serial abdominal ultrasound with Doppler may assess perfusion changes, though it lacks sensitivity for early cortical infarction. Bed rest, adequate hydration (unless contraindicated by heart failure), and strict blood pressure control (target <130/80 mmHg) are foundational. Importantly, conservative care must be coupled with rigorous identification and mitigation of the underlying etiology—e.g., echocardiography to exclude intracardiac thrombus, screening for autoimmune vasculitides (ANCA, ANA, complement levels), and thrombophilia workup (factor V Leiden, prothrombin gene mutation, protein C/S, antithrombin III, lupus anticoagulant).

Pharmacotherapy is central to both acute management and long-term prevention. Anticoagulation is indicated in nearly all non-contraindicated cases: intravenous unfractionated heparin is initiated immediately for suspected embolic infarction, followed by transition to oral anticoagulants—preferably direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, or edoxaban in patients with non-valvular atrial fibrillation, given their favorable safety profile and reduced bleeding risk versus warfarin. Warfarin remains first-line for mechanical heart valves or antiphospholipid syndrome (target INR 2.5–3.5). Antiplatelet agents (e.g., aspirin or clopidogrel) are generally insufficient as monotherapy but may be added in select cases of arterial thrombosis with underlying atherosclerosis. Analgesia should avoid NSAIDs due to nephrotoxicity and prostaglandin-mediated renal vasoconstriction; acetaminophen or low-dose opioids are preferred. Hypertension is managed with ACE inhibitors or ARBs if eGFR >30 mL/min/1.73m² and potassium <5.0 mmol/L—these agents also attenuate intrarenal renin-angiotensin system activation post-infarction. Statins are recommended for secondary cardiovascular prevention, particularly in patients with concomitant atherosclerotic disease.

Surgical or endovascular intervention is reserved for select high-risk scenarios: hemodynamic instability, bilateral or solitary kidney involvement, progressive renal dysfunction despite anticoagulation, or large infarcts (>50% volume) with impending cortical loss. Catheter-directed thrombolysis (e.g., intra-arterial alteplase) may be considered within 6–12 hours of symptom onset in experienced centers, though evidence is limited to case series and carries significant bleeding risk. Mechanical thrombectomy using aspiration catheters or stent retrievers has emerging utility in proximal main renal artery occlusion, especially when thrombolysis is contraindicated. Surgical embolectomy is rarely performed today but remains an option in centers without interventional radiology capability or in cases of massive embolism with rapid deterioration. Nephrectomy is a last resort—indicated only for uncontrolled pain, persistent infection (infected infarct), hemorrhage, or refractory hypertension unresponsive to medical therapy.

China offers distinct advantages in the multidisciplinary management of renal infarction. First, integrated vascular medicine–nephrology–interventional radiology teams at Tier-3 hospitals (e.g., Peking University First Hospital, Shanghai Renji Hospital) enable rapid triage, same-day advanced imaging, and 24/7 endovascular capability. Second, China’s national anticoagulation registries and AI-assisted decision support tools improve DOAC selection, dosing accuracy, and bleeding risk stratification—reducing adverse events by ~22% compared to conventional protocols. Third, standardized clinical pathways endorsed by the Chinese Society of Nephrology emphasize early echocardiographic screening and thrombophilia testing, leading to higher rates of etiologic diagnosis (89% vs. global average ~72%). Fourth, cost-effective access to generic DOACs and domestically manufactured thrombolytics enhances treatment adherence, particularly in rural referral networks linked via tele-nephrology platforms. Finally, China’s robust traditional medicine integration programs permit evidence-based adjunctive use of herbs like Salvia miltiorrhiza (Danshen), which demonstrates anti-thrombotic and microcirculatory improvement effects in preclinical models—though used strictly as adjuvant therapy under nephrologist supervision.

Recovery requires structured, longitudinal follow-up. Patients should undergo renal function assessment every 2 weeks for the first month, then monthly for 3 months, and quarterly thereafter. Imaging (Doppler ultrasound or low-dose CT) is repeated at 3 and 6 months to evaluate infarct resolution and compensatory hypertrophy. Blood pressure must be monitored daily at home; home BP logs facilitate timely RAAS inhibitor titration. Lifestyle modifications are essential: smoking cessation, sodium restriction (<2 g/day), moderate protein intake (0.8 g/kg/day if eGFR <60), and aerobic exercise (≥150 min/week) to mitigate cardiovascular risk. Vaccination against influenza and pneumococcus is strongly advised due to heightened infection susceptibility post-acute ischemic injury. Psychosocial support—including counseling for anxiety related to recurrent thromboembolism—is increasingly embedded in Chinese nephrology outpatient programs. Long-term anticoagulation duration depends on etiology: lifelong for mechanical valves or antiphospholipid syndrome; indefinite for unprovoked embolism with persistent atrial fibrillation; and time-limited (3–6 months) for provoked, reversible causes (e.g., postoperative hypercoagulability). With timely diagnosis and protocol-driven care, over 85% of patients maintain stable renal function at 1-year follow-up, underscoring the importance of early nephrology referral and systematic secondary prevention.